Development process of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE (DosE FIndiNg Extensions) study
Olga Solovyeva(Institute of Cancer Research), Christina Yap(Institute of Cancer Research), Munyaradzi Dimairo(University of Sheffield), Sarah Hughes, Shing Yip Lee(Griffith University), Lesley Roberts(University of Southampton), Dawn P. Richards(Robarts Clinical Trials), Adrian Mander(MRC Biostatistics Unit), Dhrusti Patel(Institute of Cancer Research), Sally Hopewell(University of Oxford), Thomas Jaki(MRC Biostatistics Unit), An‐Wen Chan(World Health Organization), Khadija Rantell, Johann S. de Bono(Royal Marsden NHS Foundation Trust), Aude Espinasse(Institute of Cancer Research), Richard Stephens(Keele University), Andrew Kightley, JEFF EVANS(Intermountain Healthcare), Siew Wan Hee(University of Warwick), John P. Kirkpatrick(Duke University), Moreno Ursino(Inserm), Alun Bedding(Roche (United Kingdom)), Christopher J. Weir(University of Edinburgh)
Cited by 0
Related Papers
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
CONSORT 2010 statement: extension to randomised pilot and feasibility trials
|Pilot and Feasibility Studies|2016|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k